The key data for treating clinically suspect arthralgias (CSA): TREAT-EARLIER (MTX) ARIAA, APIPPRA (abatacept) but what we need to do going forward: stratify pts better for studies predict individual risk better, to weight up risk-benefit of intervention #EULAR2023 @RheumNow https://t.co/h3gNIyLxPY

Key arguments for CSA skeptics: - definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is - we still struggle to prevent RA - it’s easy to go down a therapeutic slippery slope, and hard to track back - labels are hard to remove #EULAR2023 @RheumNow https://t.co/4adop3IR8g

ILD in RA and PsA @AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD. ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis. https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N

• https://bit.ly/3oIxxnR

Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8

Clinically suspect arthralgia-what is needed are predictors that enrich WHO will develop RA. Otherwise in 85% of Pts your (sham) Rx will work. If we need to reset the immune response- early makes sense but many will NOT have #RA over the next few yrs. ⁦@RheumNow⁩ #EULAR2023 https://t.co/vDv6cHqFUn

#Clinically suspect #arthralgia debate ⁦BE CAREFUL how you apply the criteria as sensitivity / specificity will vary if low pretest likelihood. ⁦@eular_org⁩ ⁦@RheumNow⁩ https://t.co/2XAwXbp1fi